Sars-CoV-2 seroprevalence in pregnant women in Kilifi, Kenya from March 2020 to March 2022

Bibliographic Data

ID22090045
AuthorsAngela Koech (0000-0003-4838-3269, Aga Khan University Nairobi, corresponding author), Geoffrey Omuse (0000-0002-3866-5118, Aga Khan University Nairobi), Alex G Mugo (0009-0003-7968-0538, Aga Khan University Nairobi), Isaac Mwaniki (Aga Khan University Nairobi), Isaac G Mwaniki, Joseph Mutunga (Aga Khan University Nairobi), Joseph M Mutunga, Moses Mukhanya (Aga Khan University Nairobi), Moses W Mukhanya, Onesmus Wanje (Aga Khan University Nairobi), Grace Mwashigadi (0000-0002-6321-3287, Aga Khan University Nairobi), Grace M Mwashigadi, Geoffrey Katana (0000-0002-3124-6615), Geoffrey G Katana, Rachel Craik (0000-0001-7885-0775, King's College London), Peter Von Dadelszen (0000-0003-4136-3070, King's College London), Kirsty Le Doare (0000-0002-5104-085X, St George's, University of London), Marleen Temmerman (0000-0003-2069-8752, Ghent University), periCOVID-Africa periCOVID-Africa, The PRECISE Network
Year2023
Volume11
Pages1292932-1292932
Publication date2023-12-19
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueFrontiers in Public Health (JOURNAL)
Journal identifiersISSN: 2296-2565 • E-ISSN: 2296-2565
PublisherFrontiers Media SA (PUBLISHER • CH)
DOI10.3389/fpubh.2023.1292932
PMID38169905
OpenAlexW4390035094
LanguageEN
Citations received2
References cited29

Background: Seroprevalence studies are an alternative approach to estimating the extent of transmission of SARS-CoV-2 and the evolution of the pandemic in different geographical settings. We aimed to determine the SARS-CoV-2 seroprevalence from March 2020 to March 2022 in a rural and urban setting in Kilifi County, Kenya. Methods: We obtained representative random samples of stored serum from a pregnancy cohort study for the period March 2020 to March 2022 and tested for antibodies against the spike protein using a qualitative SARS-CoV-2 ELISA kit (Wantai, total antibodies). All positive samples were retested for anti-SARS-CoV-2 anti-nucleocapsid antibodies (Euroimmun, ELISA kits, NCP, qualitative, IgG) and anti-spike protein antibodies (Euroimmun, ELISA kits, QuantiVac; quantitative, IgG). Results: A total of 2,495 (of 4,703 available) samples were tested. There was an overall trend of increasing seropositivity from a low of 0% [95% CI 0-0.06] in March 2020 to a high of 89.4% [95% CI 83.36-93.82] in Feb 2022. Of the Wantai test-positive samples, 59.7% [95% CI 57.06-62.34] tested positive by the Euroimmun anti-SARS-CoV-2 NCP test and 37.4% [95% CI 34.83-40.04] tested positive by the Euroimmun anti-SARS-CoV-2 QuantiVac test. No differences were observed between the urban and rural hospital but villages adjacent to the major highway traversing the study area had a higher seroprevalence. Conclusion: Anti-SARS-CoV-2 seroprevalence rose rapidly, with most of the population exposed to SARS-CoV-2 within 23 months of the first cases. The high cumulative seroprevalence suggests greater population exposure to SARS-CoV-2 than that reported from surveillance data

2019-20 coronavirus outbreak · Antibody · Biology · Obstetrics · Outbreak · Pregnancy · Serology · Seroprevalence · COVID-19 Impact on Reproduction · Medicine · SARS-CoV-2 and COVID-19 Research · SARS-CoV-2 detection and testing · Immunology · Internal Medicine · Virology

Tools

Open DOIOpen Access